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Hemophagocytic lymphohistiocytosis (HLH) is a rare, hyperinflammatory syndrome characterized by clinical signs and symptoms
of extreme inflammation. In adults, HLH is typically a complication of infections, autoimmune diseases, and malignancies. While
the disease is often fatal, classic management of HLH revolves around early diagnosis and initiation of protocolized therapy. We
present a case of a previously healthy 56-year-old female who developed distributive shock requiring intubation, vasopressors,
and continuous venovenous hemofiltration. In the setting of multiple infectious syndromes, severe cytopenias, and rising direct
hyperbilirubinemia, her diagnosis of HLH was confirmed. Therapy was initiated with dexamethasone and two doses of reduced-
intensity etoposide based on the patient’s clinical course. Over the next few weeks, she continued to improve on dexamethasone
monotherapy and has maintained remission up to the present with complete resolution of her cytopenias and return of baseline
renal function. Our case highlights the variability in the management of probable infection-associated HLH (IHLH) with a good
patient outcome. We demonstrate the potential to treat IHLH with partial protocols and minimal chemotherapeutics.
1. Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare, hyper-
inflammatory syndrome characterized by clinical signs and
symptoms of extreme inflammation [1]. There are revised cri-
teria for establishing the diagnosis of HLH from the Histiocyte
Society based upon the clinical, laboratory, and histopatho-
logic findings (Table 1). HLH is not a single disease but instead
represents a collection of disease processes with a similar end-
stage phenotype [2]. HLH has been described as a primary
disorder (i.e., familial or genetic HLH) and also secondary
to other disease processes. While both forms of HLH are
associated with high morbidity and mortality, secondary
HLH occurs in the setting of infectious, malignant, rheuma-
tologic, or metabolic conditions [3]. Occasionally, an inciting
trigger is not identified and HLH is considered idiopathic [4].
We will present a case of septic shock with subsequently
diagnosed HLH treated successfully without conventional
therapy. We provide an overview of the clinical presentation,
hospital timeline, and antimicrobial therapy in Tables 2–5
and Figures 1–4.
2. Case Presentation
A 56-year-old African American female with no significant
past medical history presented with one week of fatigue, nau-
sea, vomiting, diarrhea, intermittent abdominal pain, and
subjective fever. Laboratory investigation revealed a serum
creatinine of 2.7mg/dL with baseline creatinine of 0.8mg/dL.
Renal ultrasound was normal without evidence of obstruc-
tion. Computed tomography of the abdomen and pelvis
was negative for acute intraabdominal pathology. She was
admitted for supportive care and volume repletion for acute
renal insufficiency.
Three days after admission, her gastrointestinal symp-
toms abated, but she developed a productive cough and
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leukocytosis. Chest X-ray showed increased interstitial
markings consistent with atypical pneumonia versus inter-
stitial edema, and she was started on antibiotics. She contin-
ued to worsen clinically developing fevers, tachypnea,
hypotension, and atrial fibrillation with rapid ventricular
response.
She had negative thromboembolic and viral infectious
workups includingHIV, Epstein-Barr virus, cytomegalovirus,
parvovirus B19, human herpes virus-6, and endemic fungal
infections. She met criteria for distributive shock, and antibi-
otic coverage was broadened. Platelet count dropped from
162 × 103/μL to 51 × 103/μL in the setting of progressive
respiratory distress requiring intubation, vasopressor sup-
port, and continuous venovenous hemofiltration (CVVH).
Thrombocytopenic workup revealed elevated D-dimer,
elevated haptoglobin, negative serotonin release assay, no
red blood cell fragmentation, and only mildly reduced
ADAMTS13 activity. Total bilirubin was 22.3mg/dL with
direct bilirubin of 18.4mg/dL. Reimaging of the abdomen
and pelvis revealed findings suggestive of acalculus chole-
cystitis, splenomegaly, and thickened gallbladder wall with-
out obstruction. Hepatobiliary iminodiacetic acid (HIDA)
scan was nondiagnostic. Endoscopic retrograde cholangio-
pancreatography (ERCP) was deferred due to severe throm-
bocytopenia. A transjugular liver biopsy revealed acute
cholangitis, and she received percutaneous cholecystostomy
and a course of meropenem.
With ongoing and nondiagnosed cytopenias, bone mar-
row biopsies were performed. First attempt bone marrow
specimens were inadequate for analysis. Eventually speci-
mens revealed macrophages with evidence of hemophagocy-
tosis concerning for HLH. The patient met 7 of 8 criteria for
establishing a diagnosis of HLH (fever, splenomegaly, cytope-
nias of at least two cell lines, hypertriglyceridemia, histiocytic
hemophagocytosis, hyperferritinemia, and elevated soluble
CD-25).
She was initiated on HLH-94 protocol with dexametha-
sone and etoposide. Given her significant renal impairment,
etoposide was administered twice in the first week at 75%
of the recommended dose (i.e., 40mg/m2) based on a
Table 1: Diagnostic criteria for HLH∗.
Fever ≥ 38 5°C
Splenomegaly
Peripheral blood cytopenia, with at least two of the following:
Hemoglobin < 9 g/dL (hemoglobin < 10 g/dL for
infants < 4weeks)
Thrombocyte count < 100 × 103/μL
Absolute neutrophil count ANC < 1000/μL
Fasting triglycerides > 265mg/dL and/or fibrinogen < 150mg/dL
Hemophagocytosis in bone marrow, spleen, lymph node, or liver
Low or absent NK cell activity
Ferritin > 500 ng/mL
Elevated soluble CD-25 (soluble IL-2 receptor alpha) two
standard deviations above age-adjusted laboratory-specific norms
(or >2400U/mL often cited in the literature)
∗≥5/8 criteria must be met for the diagnosis. Adapted from Jordan et al. [3]
Table 2: HLH diagnostic criteria and patient’s presentation.
HLH-2004 diagnostic criteria
Fever +
Splenomegaly +
Cytopenia of ≥2 cell lines +
Triglyceride ≥ 254mg/dL +
Fribrinogen ≤ 150mg/dL −
Histiocytic hemophagocytosis +
NK cell activity Normal
Ferritin > 500 ng/mL + (2,455 ng/mL)
Elevated soluble CD-25 + (2,661U/mL)
Table 3: Overview of patient with HLH associated with severe
sepsis and septic shock.
Features consistent with severe sepsis and septic shock
Systemic inflammatory
response syndrome
+
Infection Unidentifiable
Hypotension requiring
vasopressors
+
Acute respiratory distress
syndrome requiring
mechanical ventilation
−
Acute renal failure requiring
dialysis
+
Altered mental status +
Lactate > 2mmol/L + (4.1mmol/L)
Platelet count < 100 × 103/μL + (15 × 103/μL)
Disseminated intravascular
coagulation
−
Other clinical and laboratory features
Anasarca −
Hepatomegaly −
Peak AST (IU/L) 174
Peak ALT (IU/L) 192
Peak LDH (IU/L) 285
Peak total bilirubin (mg/dL) 22.3
Peak direct bilirubin (mg/dL) 18.4
Peak prothrombin time (s) 26.6
Nadir hemoglobin (g/dL) 5.7 (on hospital day 20)
Nadir absolute neutrophil
count (cells/mm3)
1,600 (on hospital day 26)
Other features
Pericardial effusion, pneumonia,
acalculus cholecystitis, acute
cholangitis,
abdominal wall abscess
secondary to cholecystostomy tube
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creatinine clearance less than 10 milliliters per minute. At the
time of her second week of etoposide administration, the
patient decompensated in the setting of an abdominal wall
abscess associated with the aforementioned cholecystostomy
drain. Continued etoposide protocol was deferred given the
patient’s immune suppression, dramatically worsened clini-
cal status, and risk for toxicity in the setting of concomitant
renal and liver dysfunction. Over the course of the next few
weeks, she continued to improve without bleeding complica-
tions on dexamethasone monotherapy and supportive plate-
let and packed red blood cell transfusions.
Dexamethasone therapy was administered intravenously
for the five weeks the patient remained hospitalized, then
the patient was transitioned to oral dexamethasone for
the remaining three weeks of the eight-week taper. She
followed up monthly in the hematology/oncology clinic
and maintained remission up to the present (14 months
after admission) with complete resolution of cytopenias and
return of baseline renal function.
3. Discussion
Repeatedly, the literature suggests that it is necessary to iden-
tify and diagnose HLH early to improve mortality. As a result
of attempting to diagnose HLH early, diagnostic criteria have
been criticized for their nonspecificity [5]. HLH is believed to
be overdiagnosed due to these nonspecific diagnostic criteria
[2]. Studies show that 60% of patients with severe sepsis
and thrombocytopenia will demonstrate histiocytic hemo-
phagocytosis [6]. Because these diagnostic features are
not uncommon in severe sepsis, this suggests that there is
much ambiguity about both the diagnosis and, subsequently,
the management.
Given our patient’s instability and multiple infectious
syndromes, genetic testing for primary HLH was foregone.
However, primary HLH was thought to be less likely due to
the patient’s age, no known familial mutations, and no family
history of death of a young family member with unexplained
fever [7]. Notably, primary HLH cannot be excluded espe-
cially considering literature suggesting that primary HLH is
often set off by an infectious, malignant, or rheumatologic
trigger [4, 8]. In the absence of known malignancy or rheu-
matologic disease, her multiple infectious syndromes were
the most likely trigger of her HLH diagnosis.
Core to the uncertainty of infection-associated HLH
(IHLH) management, it has previously been postulated that
IHLH does not represent a distinct disease at all, but simply
lies on the extreme end of the inflammatory spectrum of sep-
sis [9]. Benign histiocytic proliferation in the setting of infec-
tion was first described in 1979 by Risdall et al. [10]. Risdall
et al. and other more recent literature have posited that
patients do better with supportive care than the more radical
and necessary treatment used in familial HLH [10, 11]. In
contradiction to other literature suggesting that patients with
IHLH should be treated on an HLH protocol [6, 12], we dem-
onstrate the potential to treat IHLH with tailored therapy
based on the patient’s clinical scenario which may not require
full-protocol chemotherapeutic agents for full recovery.
Table 4: Course of illness.
Course of illness
Onset of shock Day 8
Intubated Day 8
Vasopressor initiation Day 8
CVVH initiated Day 11
First bone marrow biopsy Day 11
Imaging suggestive of
acalculus cholecystitis
Day 14
Percutaneous cholecystostomy Day 15
Liver biopsy and second bone
marrow biopsy
Day 17
Extubated Day 18
Liver biopsy reveals acute
cholangitis
Day 19
HLH diagnosis made Day 22
Initiation of HLH
dexamethasone therapy
Day 22
Initiation of HLH etoposide
therapy
Day 24
Repeat vasopressor initiation Day 30
CVVH discontinued Day 44
Discharged to rehabilitation
facility
Day 56
Treatment
2 doses of etoposide 40mg/m2 and
dexamethasone per HLH-94
Outcome
Complete remission (full recovery of
cytopenias and return to baseline
renal function)
Table 5: Antimicrobial course.
Antimicrobial
Day after
admission
Azithromycin 500mg oral one-time dose Day 4
Azithromycin 250mg oral daily Day 5
Moxifloxacin 400mg oral daily Day 6
Vancomycin 1.25 g load and
Piperacillin/Tazobactam 3.375 gm intravenous
every 8 hours
Day 7-Day 11
Azithromycin 500mg intravenous daily Day 8-Day 11
Meropenem 1 g intravenous every 8 hours Day 12-Day 24
Acyclovir 400mg oral twice daily Day 23-Day 34
Discontinuation of all antibiotics Day 25
Vancomycin 2 g intravenous one-time dose Day 30
Piperacillin/Tazobactam 3.375 g intravenous
every 12 hours
Day 30-Day 36
Acyclovir 200mg oral twice daily Day 30-Day 47
Ampicillin 2 g intravenous daily Day 37-Day 56
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HLH guidelines for diagnosis and therapy are largely
based on pediatric patient populations who demonstrated
significant mortality benefit while following the therapeutic
protocol [5, 13, 14]. Furthermore, the benefits of etoposide
have been best described in viral IHLH [10–12, 15]. However,
the literature continues to demonstrate the variability within
the disease process, and there have been efforts to refine
diagnosis and treatment based upon disease severity [3, 4].
It would seem that HLH subsets (i.e., adults and nonviral
infection-associated HLH) may require therapeutic regimens
different from those described in the HLH-94 and HLH-2004
protocols.
Our patient highlights the difficulties of managing such
an adult patient with probable nonviral IHLH. There were
several factors that made our case particularly challenging:
multiple infectious syndromes, acute renal failure increasing
the toxicity of etoposide, and delay in diagnosis due to inad-
equate first bone marrow sampling. Furthermore, our patient
was at a very high risk of additional infections and further
inflammation as she was immunosuppressed with chemo-
therapeutic agents per the HLH protocol. It is not clear that
two doses of reduced-intensity etoposide caused clinical dete-
rioration; however, full-protocol etoposide was not necessary
for successful treatment. Notably, the continued dexametha-
sone monotherapy did not result in further deterioration.
While clinical courses and management of HLH vary
widely, there are even case reports of HLH patients who
improve spontaneously [16, 17]. Some patients diagnosed
with secondary HLH survive with plasma exchange or
immune globulin and without chemotherapy [18]. Given
the paucity of literature regarding reduced-intensity, mono-
therapy, or alternative HLH treatment of nonviral IHLH, it
is difficult to generalize suggested treatment regimens. How-
ever, our case suggests that a modified etoposide regimen
may be appropriate in cases when there is clinical deteriora-
tion associated with etoposide initiation. Furthermore, dexa-
methasone monotherapy may be sufficient therapy for
successful management in nonviral IHLH. This notion is
somewhat contradictory to older observational studies
indicating that rapid initiation of etoposide therapy is the
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Figure 1: Overview of patient ferritin levels with indication of dexamethasone and etoposide initiation.
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Figure 3: Overview of patient total bilirubin levels with indication of dexamethasone and etoposide initiation.
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only factor significantly associated with increased survival in
selected adult patients with secondary HLH [11, 15]. Addi-
tionally, not all patients with secondary HLH require pro-
longed therapy, and, in many cases, treatment can be
discontinued once their condition improves and the underly-
ing condition has been treated [2]. The difficulty is identify-
ing when chemotherapeutics are unnecessary and
potentially detrimental. Additional reports of modified ther-
apies for nonviral IHLH are needed to provide further guid-
ance and protocols.
Our case highlights the variability in the management of
adult IHLH with a good patient outcome. We demonstrate
the potential to treat probable IHLH with a modified chemo-
therapeutic regimen. Given the infectious nature of our case,
it would support the notion that IHLH does not represent a
distinct disease at all, but IHLH may simply lie on the
extreme end of the inflammatory spectrum of sepsis. Further
study is needed to protocolize initiation of chemotherapeu-
tics and deescalation of HLH-specific therapy especially in
patients at high risk of infections.
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